RxDoctor Payments Data

Jennifer Rose

Primary Care · Muscle Shoals, ALNPI 1720754674

Payments from drug & device makers

What this record shows

17 manufacturers reported payments, led by Intuitive Surgical at 54.5% of the total. Reporting peaked in 2024 at $2,192 and has fallen 89.4% since, to $233 in 2025.

$2,927in general payments, 2019–2025

Across 95 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • AbbVie$383
  • Lilly USA, LLC$304
  • AstraZeneca$188
  • Novo Nordisk$151
  • Bayer$68
  • plus $238 from 11 others

What the payments were for

  • Travel & lodging$1,59655%
  • Food & beverage$1,33245%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,927 in reported general payments places this provider in the 75th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$34,403
Medicare patients
154
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$16,546
EliquisApixaban18$12,038
Levothyroxine Sodium37$413
Losartan Potassium30$402
Atorvastatin Calcium35$386
Omeprazole28$324
Fluticasone Propionate17$282
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$276
Gabapentin33$267
Metoprolol Succinate18$261
Pantoprazole Sodium18$233
Montelukast Sodium21$204
Tamsulosin Hcl12$200
Lisinopril22$197
Escitalopram Oxalate19$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$304$16,54616 claims
PfizerEliquis$29$12,03818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 159 primary care providers in Alabama.

Other primary care in Muscle Shoals

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →